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20th century. Relevant techniques include (among others) organs-
on-a-chip (microdevices containing cells and fluids intended to 
simulate physiological processes in organs); organoids (three-di-
mensional spheroids containing multiple cell types and intended 
to simulate physiological processes); high-throughput systems 
(rapid screening of large numbers of chemicals for biological ac-
tivity against panels of different cells or biomolecules); induced 
pluripotent stem cells (adult cells that have been genetically repro-
grammed to an embryonic stem cell-like state); and computation-
al modeling (using computation to study the behavior of complex 
systems).
In our view, these methods (and no doubt others in various 
stages of development) have the potential to replace the use of 
animals as the default option in both safety testing and biomed-
ical research. That is, these methods will come to comprise the 
rule, with animal experiments being the exception. This is con-
sistent with Dutch efforts to expeditiously end animal experi-
1  Introduction
The Principles of Humane Experimental Technique, the landmark 
book that gave us the 3Rs framework of replacement, reduction, 
and refinement, turns 60 this year. First published in 1959, Prin-
ciples was the outcome of a project spearheaded by the Universi-
ties Federation for Animal Welfare (UFAW), overseen by a com-
mittee that included future Nobel Prize-winning scientist Peter 
Medawar, and carried out by the British scientists William Rus-
sell and Rex Burch (Russell and Burch, 1959). The 3Rs frame-
work helped to inspire and guide humane progress in experimen-
tal technique during the second half of the 20th century and be-
yond (Stephens and Mak, 2013; Balls et al., 2019). 
The 60th anniversary of Principles falls in the midst of sub-
stantial developments in non-animal methods, i.e., potential re-
placement technology. Indeed, scientific experimentation is at 
the cusp of a new era of techniques hardly imagined in the mid- 
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Abstract
This year marks the 60th anniversary of Russell and Burch’s pioneering book, The Principles of Humane Experimental 
Technique. Their 3Rs framework has helped to inspire humane and scientific progress in experimental technique. However, 
it is time to update its strategic application. The 21st century has already seen the development of promising, high-tech 
non-animal models, such as organs-on-a-chip and computational approaches that, in our view, will replace animals as 
the default option in biomedical experimentation. How fast this transition will take place will depend on the pace at which 
these new models are optimized to reflect the biology of humans, rather than that of non-human animals. While the new 
methods are likely to reshape all areas in which animals are currently used in science, we particularly encourage their 
application in biomedical research, which accounts for the bulk of animals used. We call for the pursuit of a three-prong 
strategy that focuses on (1) advancing non-animal methods as replacements of animal experiments, (2) applying them 
to biomedical research, and (3) improving their relevance to human biology. As academics and scientists, we feel that 
educational efforts targeted at young scientists in training will be an effective and sustainable way to advance this vision. 
Our strategy may not promise an imminent end to the use of animals in science, but it will bring us closer to an era in which 
the 3Rs are increasingly perceived as a solution to a receding problem. Russell and Burch themselves surely would have 
welcomed these positive changes. 
This is an Open Access article distributed under the terms of the Creative Commons 
Attribution 4.0 International license (http://creativecommons.org/licenses/by/4.0/), 
which permits unrestricted use, distribution and reproduction in any medium, provi-
ded the original work is appropriately cited. 
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The high numbers of animals used in biomedical research 
warrant additional emphasis to replace their use in these fields. 
Although toxicity testing accounts for less than 10% of animal 
use in science, much of the attention of the 3Rs to date has been 
focused on this area (Stephens and Mak, 2013). The reasons for 
this include the limited number of targets for replacement in this 
field, public concern over this type of animal testing, and the pos-
sibility to gain government approval for developed replacement 
tests. In contrast, biomedical research is a far more diverse and 
decentralized area, where, in principle, originality and innovation 
are most highly prized. Thus, this field presents a different set of 
challenges to replacement advocates. However, the new non-ani-
mal methods offer human-relevant insights and diverse high-tech 
research opportunities, which can be adapted to specific research 
needs. Importantly, changing to non-animal methods in this field 
is a matter of choice based on knowledge as well as on funding, 
but it is not determined by regulatory requirements. 
3  The expanding toolbox of non-animal methods  
and approaches
In their chapter on replacement, Russell and Burch (1959) not-
ed that “(m)ammalian tissue cultures … have become, since the 
Second World War, one of the most important replacing tech-
niques, and indeed one of the most important developments in 
biology” (p. 72). This development was facilitated by the discov-
ery of antibiotics, which suppress the growth of bacteria that of-
ten contaminate cell cultures. During the balance of the twenti-
eth century, tissue culture began to be applied in a wide array of 
fields. However, this technique was largely limited to homoge-
nous, two-dimensional arrays, short-lived in vitro preparations, 
and relatively crude reconstructed tissue.
Today, the in vitro/cell culture toolbox is much more sophisti-
cated and diverse. It includes organ-on-a-chip microphysiologi-
cal systems (Andersen et al., 2014; Marx et al., 2016); three-di-
mensional organoids containing multiple cell types; robot-assist-
ed, high-throughput systems (van Vliet et al., 2014); high-content 
imaging technologies; and DNA or RNA microarray screening. 
Also available are computational tools and approaches, machine 
learning and artificial intelligence (AI) to help make sense of “big 
data” (Hartung and Hoffman, 2009; Hartung, 2016, 2018; Luec-
htefeld et al., 2018). 
These methods have a number of advantages over 20th centu-
ry in vitro approaches, which can include speed, throughput, and 
biological relevance. Multiple cell types, 3D architecture, fluid 
exchange, etc. enable the models to function more like human 
tissues or organs and to survive in culture for longer time periods. 
Owing to the development of induced pluripotent stem cells, the 
models can now be seeded with non-cancerous, differentiated hu-
man cells and, thanks to microphysiological systems technology, 
different “organs” can be connected with one other. 
Much has already been written about these and other 21st cen-
tury tools and approaches (Langley et al., 2017; Noor, 2019; 
Wilkinson, 2019; Benam et al., 2019; Bowman et al., 2018; Savo-
ji et al., 2019; Marshall and Willett, 2018; Marshall et al., 2018; 
Boeckmans et al., 2018; Pistollato et al., 2016; Langley et al., 
mentation in that country, primarily through vigorous develop-
ment and application of alternative methods (Netherlands Na-
tional Committee for the protection of animals used for scientific 
purposes, 2016). The emphasis in the 21st century is likely to be 
on expanding and exploring the capabilities of these non-animal 
methods further and using them to better understand human bi-
ological pathways and the perturbations to these pathways that 
can cause disease. 
In this perspective paper, we take the anniversary of Principles 
as an opportunity to reflect on these issues and comment on pri-
orities that the 3Rs community and like-minded scientists should 
consider adopting as we move forward. We briefly describe the 
scale of animal use in science and comment on 21st century meth-
ods and approaches before introducing our overaching strategy 
and concluding with remarks regarding Russell and Burch. 
2  The global scale and nature of animal  
experimentation
When Russell and Burch examined the “ecology of experimental 
animals,” their focus was limited to Great Britain, where the gov-
ernment had long published fine-grained annual statistics on lab-
oratory animal use. They estimated that almost 1.8 million verte-
brates were used in 1955 (Table 4 in Russell and Burch, 1959). 
This number has increased to 5.53 million animals (Home Office, 
2018). Although the latter part of the 20th century saw a sizable 
decline in animal use in Great Britain and elsewhere (De Greeve 
et al., 2004), that trend reversed when the genetic modification of 
animals became possible (Ormandy et al., 2009). 
Only rough estimates exist for global animal use as many coun-
tries appear not to publish their animal use statistics. It was esti-
mated that more than 127 million vertebrate animals were used 
worldwide for scientific purposes in 2005 (Knight, 2008) and this 
number has increased further since then (Taylor and Rego Al-
varez, 2019). Novel, straightforward genetic modification tech-
niques such as CRISPR will likely lead to a further increase in the 
number of genetically modified animals being created, bred and 
used, and also to genetic modifications of further species (Bailey, 
2019). 
In the European Union (EU), and perhaps elsewhere, basic and 
applied research accounts for most of the animals used in science, 
as indicated in the “Seventh report on the statistics on the number 
of animals used for experimental and other scientific purposes” 
released by the European Commission (EC, 2011). Other catego-
ries of use include production and quality control of devices and 
products used in human medicine and dentistry, and toxicologi-
cal and other safety tests, among others. Between 1995 and 2011, 
about 65% of animals were used in basic and applied research by 
the 15 EU Member States (at the time) plus Switzerland (Dane-
shian et al., 2015). In 2016, 47% of procedures were conducted 
for basic research and 21% for applied research based on the na-
tional statistics of 26 reporting EU Member States (Taylor and 
Rego Alvarez, 2019). Directive 2010/63/EU (EU, 2010) has put 
in place a more comprehensive reporting framework for Member 
States; as a result, more precise estimates of animal use in the EU 
will be available in the next overall report due in late 2019. 
Herrmann et al.
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imal-free methods to address human relevance in the years since 
then.
4.1  Prioritizing replacement
In some respects, prioritizing replacement in the era of 21st cen-
tury technology is simply an extension of Russell and Burch’s 
thinking that reduction and refinement are interim steps on the 
path towards replacement. They wrote:
“… refinement is never enough, and we should always 
seek further for reduction and if possible replacement. 
Still more generally, replacement is always a satisfactory 
answer….” (p. 66) (Russell and Burch, 1959).
The motivating issue for them was the distress that animals could 
experience in the laboratory. They referred to this as “inhuman-
ity,” a term they sought to apply objectively without implying 
any ethical judgement of the experimenters or staff. “Direct inhu-
manity” could result from the “unavoidable consequence of the 
procedure employed,” no matter how well refined. In addition, 
“contingent inhumanity” could result as an “incidental and in-
advertent by-product of the use of the procedure, which is not 
necessary for its success” (p. 54). In their view, it was better to 
avoid both types of inhumanity by using replacement methods, 
when available.
Prioritizing replacement in the 1950s was more quixotic than 
practical. This was perhaps one reason for the delayed uptake of 
the 3Rs framework during the 1960s and 1970s (Stephens and 
Mak, 2013). Today, however, while much progress has been 
made with reduction and refinement, the replacement toolkit is 
more impressive and promising than ever. The new methods do 
not necessarily translate into direct replacements of individual 
animal models; combinations of methods may be needed to re-
place an animal model as an in vitro system is often still far less 
complex than an organism. However, suitability to answer a re-
search question depends on whether a model or model combina-
tion includes all relevant aspects of a (human) biological system, 
not whether it models an organism in its entirety. 
There are also societal reasons to favor replacement. A shift in 
focus to animal-free methods would be in line with increasing in-
ternational public concerns about laboratory animal suffering as 
shown by the Stop Vivisection initiative in the European Union1 
and recent Ipsos MORI studies conducted by research centers 
such as Pew2,3 and Gallup (Clemence and Leaman, 2016; Jones, 
2017). In addition, the EU legislation governing animal exper-
imentation not only calls for the use of non-animal methods, 
where available (EC, 2010) (Recital 11), but has as its long-term 
goal the phasing out of all animal use (EU, 2010, Recital 10). One 
might call this “full replacement” (Stephens, 2012).
In the light of insurmountable species differences (Pound and 
Ritskes-Hoitinga, 2018) and new possibilities offered by the nov-
el technologies and approaches that are human-biology based, we 
can and should put the most effort into replacing animal experi-
ments with non-animal methods. Setting a priority means empha-
2015). Here we would like to mention several recent develop-
ments that have been key in driving non-animal methods for-
ward: The U.S. National Research Council report on “Toxici-
ty Testing in the 21st Century: A Vision and a Strategy” (NRC, 
2007) and the EU legislation governing animal experimentation 
(Directive 2010/63/EU on the protection of animals used for 
scientific purposes) (EU, 2010; Hartung, 2010) created a more 
welcoming environment for the new methods and officially 
recognized their potential to replace animal use. Many of these 
tools and approaches are now commercially available, which 
has greatly increased their accessibility and diminished practi-
cal barriers to their adoption and use. Although high-throughput 
testing is limited to centralized laboratories owing to the sophis-
ticated equipment required for these arrays, median-throughput 
versions of these assays are now more widely accessible. Also, 
the focus has shifted away from 1:1 replacement of animal mod-
els to developing models with human relevance, thus enhancing 
their translational value and their acceptance in the larger scien-
tific community. “Human-on-a-chip” efforts have begun to inter-
connect numerous organ models in microphysiological arrays to 
approach the complexity of the human body and be able to iden-
tify organs affected by chemical substances (Marx et al., 2012). 
The development of these models and approaches has been fa-
cilitated by advances in stem cell technology, microengineer-
ing, microfluidics, computing power, and respective multidisci-
plinary cooperation.
4  A proposal to prioritize the 3Rs of replacement, 
research, and (human-) relevance
Not surprisingly, sixty years after Russell and Burch proposed 
the 3Rs, the landscape of animal experimentation and alterna-
tives-related technology has changed. Despite successes in devel-
oping non-animal methods, especially for toxicological testing, 
the scale of animal use in Great Britain – home of UFAW, Russell 
and Burch, and the 3Rs – has more than tripled (Home Office, 
2018). What must the 3Rs community change to become more 
effective? 
We propose a strategic focus that prioritizes: (1) replacement 
over refinement and reduction, (2) biomedical research over safe-
ty testing, and (3) relevance to humans rather than to non-human 
animals. One can think of these priorities as a new set of 3Rs 
(replacement, research, and relevance) for the current era. These 
three priorities are discussed in the following subsections.
An alternatives strategy that emphasized two of the three pil-
lars highlighted here, namely replacement over reduction and re-
finement, and biomedical research over safety testing has been 
proposed previously (Stephens, 2012). However, the importance 
of our third pillar – human relevance – has been underscored by 
recent attention to the reproducibility and translatability pitfalls 
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funded animal-based research has had on citizens’ health, so as to 
reassess how to channel funding more effectively to achieve the 
goals of biomedical research. 
Some of the approaches (if not the tools) used in toxicology 
and regulatory testing could be applicable to biomedical research 
(Gruber and Hartung, 2004). For instance, adverse outcome path-
ways (AOPs) are constructed to portray existing knowledge re-
garding the adverse effects elicited by chemicals in an agnostic 
manner. AOPs identify the molecular initiating event and inter-
mediate mechanisms (key events) underlying these effects up to 
an adverse health outcome, and span multiple levels of biologi-
cal complexity (i.e., population, organism, organ, cell, and genetic 
levels). While AOPs have been conceived in the field of toxicolo-
gy, their use would also be applicable to biomedical research, as a 
more explicit framework for mechanistic studies. For example, by 
using an AOP conceptual framework it could be possible to gather 
existing knowledge about signaling pathways that are perturbed at 
the onset and during the consolidation of a certain disease, and to 
link genetic determinants, lifestyle and environmental factors with 
adverse health effects (Langley, 2014; Pistollato et al., 2015).
An initiative aiming to further a human-focused, pathway-based 
approach to studying, preventing and treating disease is the 
BioMed 21 (Biomedical Research for the 21st Century) Collabora-
tion, which is working internationally with health experts, regula-
sizing some things over others. Issues that are no longer a priority 
are de-emphasized, not necessarily abandoned. Thus, for a fund-
ing agency, prioritizing replacement could mean that more than 
an equal share of funds go to this topic, while some funds are 
nonetheless allocated to reduction and refinement.
4.2  Prioritizing biomedical research as the target  
of non-animal methods
The major goals of biomedical research are the advancement of 
human health, the discovery of effective and safe treatments for 
humans, and the elucidation of the role of genetic and environ-
mental risk factors in the onset and the consolidation of human 
diseases. But although there is a globally recognized need to re-
place animal use in toxicology and regulatory testing whenever 
possible (Balls, 2007; Hartung, 2009; Stephens and Mak, 2013), 
this is not yet the case in basic and applied research, where most 
of the animals are used (Daneshian et al., 2015; EC, 2011). Con-
sequently, the value of animal models for biomedial research 
should be critically appraised by means of systematic reviews, 
meta-analyses, and citation analyses (e.g., Carvalho et al., 2019; 
Hartung, 2013; Herrmann, 2019a; Knight, 2019; Pound et al., 
2004). Also, with regards to research funding strategies and pri-
oritization, assessing return on investment with meaningful indi-
cators is key to enable an assessment of the impact that publicly 
Fig. 1: Schematic view of how human-based models/tools, technological approaches and readouts can be applied in biomedical 
research to promote a systems biological understanding of disease etiopathology
Optogenetics involves the use of light to monitor cells in living tissue (typically neurons) that have been genetically modified to express 
light-sensitive ion channels. Abbreviations: CSF, cerebrospinal fluid; GEP, gene expression profiling; GWAS, genome wide association 
study; HCI, high content imaging; IC, immunocytochemistry; IH, immunohistochemistry; iPSC, induced pluripotent stem cells; MEA, multi-
electrode array; MRI, magnetic resonance imaging; PET, positron emission tomography
Herrmann et al.
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Thus, the “high-fidelity fallacy” is the unfounded belief that, say, 
a mouse would be a good predictor of the human situation in a 
given context because both mice and humans are mammals. In 
contrast, an in vitro system lacks fidelity to a human situation but 
can nonetheless allow good discrimination, say, of which chem-
icals might cause skin sensitization in humans if it contains the 
relevant cell types that are involved in the human skin sensitiza-
tion process.
Clearly, the issues of model fidelity and discrimination de-
scribed in the 1950s are still relevant today. High discrimination 
yields high translatability, whereas the same cannot necessarily 
be said of high fidelity. The decades since the 1950s have given 
us ample evidence of the limited translatability of animal mod-
els to the human situation (e.g., Kramer and Greek, 2018; Pippin, 
2012). For example, the overall likelihood of approval of a poten-
tial drug from preclinical studies, which are based largely on ani-
mal studies, is less than 10% (Hartung, 2013; Thomas et al., 2016; 
Meigs et al., 2018) with efficacy and safety issues accounting for 
the majority of failures (Harrison, 2016). In light of this, the rele-
vance and reliability of animals for preclinical drug development 
have been questioned5 (e.g., Kramer and Greek, 2018; Pound and 
Bracken, 2014; Pound and Ritskes-Hoitinga, 2018; van der Worp 
et al., 2010). Current NIH director Francis Collins, in an article 
discussing the translation of basic biomedical science into safe 
and effective clinical applications, also expressed significant res-
ervations about animal models, stating that “the use of small and 
large animals to predict safety in humans is a long-standing but 
not always reliable practice in translational science” (Collins, 
2011).
Some projects are still seeking to develop better animal mod-
els of diseases, e.g., the NIH-funded MODEL-AD consortium6 
is engineering mice with different genetic mutations linked with 
early- or late-onset Alzheimer’s. However, other scientists urge 
caution: Bart de Strooper, a molecular biologist at the Catholic 
University of Leuven (KU Leuven) declared that “the biggest 
mistake you can make is to think you can ever have a mouse with 
Alzheimer’s disease” (Reardon, 2018). Investing large amounts 
of money, energy and time into the ‘remaking’ or optimizing ani-
mal models (animal models 2.0) has not mitigated the translation-
al failure (Sutherland et al., 2012; Leung et al., 2018). However, 
interviews with the animal research community on the causes of 
the low reproducibility and translatability of animal experiments 
showed no acknowledgement of limitations to extrapolating re-
sults from animals to humans (Fitzpatrick et al., 2018). A recent 
survey (Franco et al., 2018) amongst participants of laboratory 
animal science courses in four European countries (Denmark, 
Germany, Switzerland, and Portugal) revealed that animal exper-
imenters considered refinement more important and more achiev-
able than replacement. In addition, they prioritized refinement 
over reduction efforts, which is a reversal of the hierarchy pos-
tulated by Russell and Burch (Russell and Burch, 1959), who put 
replacement first and refinement last.
tory and research agencies, and funding bodies to develop innova-
tive research roadmaps that focus on understanding human disease 
pathophysiology.4 BioMed 21 envisions a “human-based pathway 
approach to human disease research” applicable to a broad range 
of human pathologies (Langley et al., 2017). The Collaboration 
aims to use technological tools and biological models within an 
AOP framework to study human pathologies, thereby promoting 
the discovery of drug targets, and possibly reducing late-stage drug 
attrition. Information is drawn from observational, prospective, 
epidemiological, and interventional studies conducted in human 
patient cohorts. The Collaboration also promotes global efforts to 
improve transparency, increase reproducibility, and confirm asso-
ciations described in epidemiological studies (Wang et al., 2016).
Complex cell models, such as human induced pluripotent stem 
cells (hiPSCs) and their differentiated derivatives obtained from 
patients and healthy subjects, are suitable for adaptation for bio-
medical research to replace animal experiments. These models 
can be cultured in 3D to improve the level of physiological com-
plexity, e.g., as organoids in microfluidic devices (Alépée et al., 
2014; Park et al., 2015; Skardal et al., 2016). Stem cell discovery 
platforms are already yielding the first clinical candidates (Mull-
ard, 2015; McNeish et al., 2015).
Proteins associated with signaling pathways and genetic/epi-
genetic factors can be studied with a wide array of omics technol-
ogies, next-generation sequencing approaches, and gene expres-
sion profiling; these, together with integrated computer modelling, 
are already paving the way for a systems-biological understanding 
of disease etiopathology (Fig. 1) without the use of non-human 
animals and thus the problem of interspecies differences.
Tools that are suitable to address population/organism bio-
logical complexity include human ex vivo material derived from 
healthy subjects and patients, such as blood and plasma samples, 
cerebrospinal fluid, post-surgical biopsies, and post-mortem tis-
sues, which can be useful to identify early biomarkers of human 
diseases. Advanced imaging technologies such as imaging con-
nectomics, which allows comprehensively mapping the neural el-
ements and inter-connections constituting the brain, are providing 
new insights into brain diseases (Fornito and Bullmore, 2015). 
Such imaging data can be associated with cognitive test scores 
and omics data, allowing multi-scale data integration (Fig. 1).              
4.3  Promoting human relevance in biomedical  
research
Prioritizing animal-free methods of high human relevance avoids 
the limited translational value of animal models to human biol-
ogy. Russell and Burch were keenly aware of the importance of 
relevance in research, whether the research was aimed at under-
standing humans or another species. They distinguished between 
models that had high fidelity versus high discrimination. The 
former were grossly similar to what was being modeled (fideli-
ty) but did not necessarily do a good job of predicting outcomes 
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mer’s disease research (Pistollato et al., 2016). Human-based 
methods should be used to elucidate disease processes at mul-
tiple levels of biological complexity (Fig. 1), such as by asso-
ciating novel human-based cellular and computational models 
with non-invasive imaging tools and epidemiological and clinical 
data to facilitate human-relevant data discovery. In this regard, 
some recent European initiatives are embracing a multidimen-
sional and multidisciplinary perspective for the study of complex 
brain interactions and Alzheimer’s disease research (Vaudano et 
al., 2015). These initiatives include the Human Brain Project7 
and the Innovative Medicines Initiative (IMI) with three com-
plementary projects: the European Medical Information Frame-
work (EMIF),8 the Aetionomy project (organizing mechanistic 
knowledge about the biological pathways involved in the aetiol-
ogy of neurodegenerative diseases, to guide the classification of 
disease classes and subclasses)9 and EPAD (European Prevention 
of Alzheimer’s Dementia Consortium).10 Similarly, in the United 
States, the Accelerating Medicines Partnership (AMP) is aiming 
to develop new diagnostics and treatments for Alzheimer’s dis-
ease, type 2 diabetes, autoimmune disorders (i.e., rheumatoid ar-
thritis and systemic lupus erythematosus), and more recently also 
Parkinson’s disease, by jointly identifying and validating new bi-
ological disease targets. The AMP is a public-private partnership 
between the National Institutes of Health (NIH), the US Food and 
Drug Administration (FDA), 12 biopharmaceutical and life sci-
ence companies and 13 non-profit organizations.11 Similar trans-
disciplinary initiatives are ongoing in other biomedical research 
areas and in other countries. 
5  Increasing awareness, dissemination and 
education on non-animal approaches
We recognize that advancing human-relevant, animal-free ap-
proaches in biomedical research should be a multi-faceted ef-
fort involving, inter alia, funding targeted at laboratory research, 
graduate and post-doctoral research fellowships, and alternatives 
prizes. However, a key step in transforming the current animal 
use paradigm is increasing the awareness of currently available 
animal-free methods. Without knowledge of these methods, sci-
entists cannot adopt them, funding agencies cannot create pro-
grams to fund them, ethical review committees cannot ask why 
they are not employed in a given protocol, and so forth. Conse-
quently, knowledge-sharing through education and training plays 
a central role in achieving the move away from animal experi-
ments and towards human-biology based research methodologies 
(Daneshian et al., 2011; Hartung et al., 2009; Herrmann, 2019a; 
Holley et al., 2016). Here we address the narrow but far-reach-
ing issue of educating future and early-career scientists on these 
issues.
Both the United States National Research Council report “Tox-
icity Testing in the 21st Century: A Vision and a Strategy” (NRC, 
2007) and Directive 2010/63/EU (EU, 2010) recognize the need 
to modernize toxicity testing and advocate an approach that em-
phasizes non-animal methods. Both documents highlight the 
need to improve human relevance, foster a paradigm shift from 
nearly exclusive reliance on animal experimentation to more hu-
man-based approaches, and introduce pathway-based approaches 
to gather a mechanistic understanding of disease etiology. These 
arguments are also applicable to biomedical research. Calls are 
becoming louder for a shift towards methods that are human bi-
ology-based and, hence, human-relevant, to avoid the inaccuracy 
in predicting efficacy and safety of drugs using current preclini-
cal animal models (Archibald et al., 2018; Herrmann and Jayne, 
2019; Kramer and Greek, 2018). 
21st century methods allow scientists to incorporate human rel-
evance as a primary design criterion of biomedical research mod-
els. In lung models, for example, relevant human cell types can 
be incorporated into a lung-on-a-chip, with mechanical forces 
mimicking the shear forces exerted during breathing (Huh et al., 
2010; Benam et al., 2017). Human samples, large data reposito-
ries, and computational and imaging tools are also available to 
carry out human-relevant biomedical research. 
Of course, no model is without its limitations; thus, 21st century 
in vitro systems also have limitations, such as lacking the inte-
gration and longevity of an intact organism. They are designed 
with the intention to simulate human biology up to a certain level 
of organization and complexity, and each system’s relevance to 
study a certain scientific problem must be carefully considered 
and verified. Also, they must be performed by trained scientists 
and follow best practice guidance to ensure quality results.
It should also be mentioned that microdosing has been recent-
ly considered a promising way to assess, by means of positron 
emission tomography (PET) and accelerator mass spectrome-
try (AMS), pharmacokinetics and pharmacodynamics of tested 
drugs administered at non-pharmacological doses to humans. 
This facilitates exploratory studies directly in humans, while re-
ducing the use of animals in preclinical toxicology (Bergstrom, 
2017). The use of microdosing has been encouraged by regulato-
ry agencies both in Europe and the United States, and a microdos-
ing regulatory framework has been accepted by the International 
Conference on Harmonization (ICH, 2009). 
The failures in drug development may be related not only to 
the use of animal models of questionable relevance to humans, 
but also to the use of these models in a hyper-reductionist ap-
proach to dissect the possible contributions of single gene(s) or 
protein(s) to the onset of complex, multi-factorial human pathol-
ogies. Some key issues should therefore be considered, in order 
to refocus current and future research strategies and priorities in 
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medicine and its translation to toxicology. Concepts of systematic 
reviews, meta-analysis, risk-of-bias, and various quality assur-
ance schemes are introduced. Both courses are offered for free 
since 2018 on the online learning platform Coursera and had reg-
istered about 2500 active learners by June 2019.
To reach early career scientists, the JRC organized a Summer 
School on “Non-animal Approaches in Science” in 2017 and 
201914 to share knowledge and expertise on the newest innova-
tive animal-free methods in research and testing and to discuss 
the place of the 3Rs in science today. A further summer school is 
planned for 2020 in the US.
The University of British Columbia (UBC) will be starting a 
course on non-animal methods in biomedical sciences.15 Also, 
the Canadian Centre for Alternatives to Animal Methods16 and 
the Canadian Centre for the Validation of Alternative Methods17 
(University of Windsor) have been developing academic pro-
grams in animal replacement science. At the undergraduate level, 
they plan to offer a minor and a certificate program for science 
majors, with the intention of developing a major degree program 
over time. At the graduate level, they are currently developing a 
one-year Master’s program on alternatives research – from sci-
ence to ethics and hands-on training in alternative test methods 
– and training doctoral students in their multidisciplinary human 
biology-based research laboratory.18
We hope that targeted courses such as these will be adopted 
into the curricula of many additional universities internationally 
to inform future and early-career scientists on state-of-the-art 21st 
century non-animal methods sustainably.
6   Conclusions 
We believe that 3Rs advocates should consider what set of prior-
ities (informed by the 3Rs) is most appropriate to their era and is 
most likely to maximize return on investment. In 2019, we pro-
pose a strategy based on prioritizing Replacement, (biomedical) 
Research, and (human) Relevance. These three Rs are not intend-
ed to replace the original set, but to represent a strategic applica-
tion of Russell and Burch’s framework to an era ripe with non-an-
imal methods, with opportunities to apply them in biomedical 
research, and with ways to craft these methods to reflect human bi-
ology. To achieve this, we embrace a fresh perspective on the way 
biomedical research is taught, planned and funded. Human-based 
models and methods, including complex in vitro systems, in silico 
tools and high-throughput approaches are now far developed and 
should be pursued in a multidisciplinary and collaborative effort 
to increase human relevance, reproducibility and, ideally, translat-
ability of scientific data, as already envisioned in the last decades 
in toxicology and regulatory testing (Gibson, 2010).
In Europe, the EU Reference Laboratory for alternatives to an-
imal testing (EURL ECVAM) of the Joint Research Centre (JRC) 
has recently coordinated a study to review available education 
and training resources that support the 3Rs approach.12 The aim 
of this study is “to identify courses, modules, teaching materials, 
guidance, and other resources to form a snapshot view of how, 
where and to whom the 3Rs principles and alternative-to-animal 
approaches are currently being taught keeping in mind that ma-
ny such initiatives might not be ‘3R labelled’”. In the JRC re-
port “Accelerating progress in the Replacement, Reduction and 
Refinement of animal testing through better knowledge sharing” 
(Holley et al., 2016), it is acknowledged that, although there are 
many available 3Rs relevant knowledge sources, their impact 
could be increased by, e.g., (i) increasing awareness and coor-
dination, and (ii) better curating existing knowledge sources. 
EURL ECVAM is currently collaborating with Directorate Gen-
eral Environment (DG ENV) on an initiative in which 3Rs ex-
perts design and produce eLearning modules for students and 
professionals involved in laboratory animal use. The modules 
cover the educational and training requirements under Directive 
2010/63/EU with special focus on replacement methods to ac-
clerate and aid the uptake of animal-free approaches in science.13 
There are currently only a few courses available at the uni-
versity level that are specifically teaching the 3Rs (Holley et al., 
2016). In the following we give a few examples of such courses. 
One is run by one of the authors (KH) at Johns Hopkins Universi-
ty as part of the educational program offered by the Center for Al-
ternatives to Animal Testing (CAAT). It is an 8-week course open 
to graduate and undergraduate students consisting of 18 lectures 
by and 10 interviews with international experts in their respective 
fields, and it is complemented by virtual tours through two lab-
oratories that use animal-free methods. The modules cover how 
to fully apply the 3Rs principles and discuss the limitations of 
animal use in science. Other topics include how to plan, conduct, 
analyze and report research studies, as well as how to properly 
formulate a research question, to conduct comprehensive liter-
ature searches, and to critically appraise the validity of animal 
and non-animal models and methods in order to choose the best 
means for particular research questions (Herrmann, 2019b). This 
course will be complemented in the next academic year by cours-
es focusing on non-animal approaches in basic and applied re-
search, the ethics of animal use in science, and best practice ap-
proaches to reduce animal suffering and improve scientific rigor. 
CAAT also offers classes on Toxicology in the 21st Century and 
Evidence-based Toxicology. Toxicology in the 21st Century ad-
dresses the current paradigm change in regulatory toxicology, the 
shortcomings of the current system, and the adaptation of novel 
technologies to overcome them. The course Evidence-based Tox-




15 Personal communication with Dr. Elisabeth Ormandy, Executive Director, Animals in Science Policy Institute and Lecturer, University of British Columbia.
16 http://www.uwindsor.ca/ccaam/ 
17 http://www.uwindsor.ca/ccaam/303/canadian-centre-validation-alternative-methods-cacvam 
18 Personal communication with Dr. Charu Chandrasekera, Executive Director, Canadian Centre for Alternatives to Animal Methods.
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We direct our proposal to scientists, advocates, funders and 
institutions who are interested in non-animal methods and ap-
proaches. These are the players who are motivated to accelerate 
progress, including through their own research, teaching, lobby-
ing, allocation of funds, and the like. 
Where does that leave Russell and Burch’s analysis and the 
3Rs framework in the 21st century? To a certain extent, all of the 
3Rs will retain some importance as long as any animals are used 
in experimentation. However, if animal experiments are eventu-
ally no longer the norm, there will inevitably be less emphasis 
on reducing and refining the remaining animal experiments (as 
important as these activities still are now). Hence our call to focus 
energies on optimizing and implementing replacement (non-ani-
mal) methods. 
Our aim is not to diminish the legacy of Russell and Burch but 
to mark the proper place of the 3Rs and to move forward towards 
a new era in the history of humane experimental technique.
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